Stock Ratings / Industrials / CUVL / forecast

CDTG (26) DXST (47) FERG (69) NKLR (32) ⌘ Pro Terminal →

Clinuvel Pharmaceuticals Limited (CUVL) 12-Month Stock Forecast & Price Target Cone

$5.15 +1.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Clinuvel Pharmaceuticals Limited (CUVL) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $257.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CUVL)Realized 20D OHLCV Swing Band: ±8.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CUVL Position Size: $10,000

Shares at $5.15: 1941.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.17

$8,097

$-1,903 (-19.0%)

12M Consensus BaseTarget $5.34

$10,369

+$369 (+3.7%)

12M Bull Case BreakoutTarget $9.37

$18,194

+$8,194 (+81.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	BUY	$9	69%	B
JP MorganUS Large-Cap Research	HOLD	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CUVL Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CUVL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.13%📐 HORIZONTAL RANGE

2026-10-30O $6.11H $6.11L $4.95C $5.15VOL 5.2K

RES: $8.22SUP: $4.64SMA50: $5.83SMA200: $6.79

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CUVL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CUVL Butterfly Map → + Track CUVL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

0.9%/yr Implied 5Y Growth

vs. +5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CUVL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CUVL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CUVL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CUVL)

Industrials Rank #108 of 485 ⚔️ CDTG vs CUVL Full Matrix →

1. Head-to-Head Industrials Peer Comparison (CUVL vs. CDTG, DXST, FERG, NKLR)

Industry: Miscellaneous (4 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Clinuvel Pharmaceuticals Limited (CUVL) ranks #108 by composite RQD confidence (66/100, grade C+) and #335 by equity capitalization ($257.8M). Within this direct 5-issuer industry benchmark cohort, CUVL leads on earnings valuation at 11.1x trailing P/E, while FERG leads on capital efficiency and profitability with 22.2% ROIC and 30.7% gross margin. FERG currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CUVL at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CUVL ACTIVE Clinuvel Pharmaceuticals Limited	C+	66/100	11.1x	81.2%	—	+1.58%	$257.8M	Benchmark Subject
CDTG CDT Environmental Technology Investment Holdings Limited	E	26/100	—	41.5%	-30.1%	-7.84%	$2.8M	/cdtg-vs-cuvl →
DXST Decent Holding Inc (Class A)	D	47/100	—	26.2%	—	+2.68%	$2.4M	/dxst-vs-cuvl →
FERG Ferguson Enterprises Inc.	C+	69/100	25.1x	30.7%	22.2%	+4.21%	$46.52B	/ferg-vs-cuvl →
NKLR Terra Innovatum Global N.V.	E	32/100	—	—	-35.0%	-2.51%	$257.5M	/nklr-vs-cuvl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001290877

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Clinuvel Pharmaceuticals Limited (CUVL) reported GAAP revenue of $61.1M (+5.5% vs. FY2024 revenue of $57.9M ) , GAAP net income of $23.1M, operating cash flow of $27.3M, and free cash flow of $27.1M (+34.9% YoY). On the balance sheet, CUVL closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$61.1M	$23.1M	$27.3M	$27.1M	—	—
FY2024 (FY)	2024-06-30	$57.9M	$23.3M	$23.8M	$20.1M	—	—

3. CUVL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CUVL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Clinuvel Pharmaceuticals Limited (NASDAQ: CUVL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $5.15 (+1.58% 1D, market cap $257.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, CUVL ranks #108 in composite RQD confidence.

How does CUVL compare to CDTG and DXST in the Industrials sector?

Within the Industrials sector (Miscellaneous), CUVL carries a Roarable C+ (66/100 RQD), trailing P/E of 11.1x, gross margin of 81.2%, and ROIC of —. By comparison, CDTG (CDT Environmental Technology Investment Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -30.1%, cap $2.8M) and DXST (Decent Holding Inc (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $2.4M). Among the 5-stock peer group, CUVL leads on earnings multiple (11.1x) while FERG leads on capital efficiency (22.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CUVL?

Per CUVL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001290877), Clinuvel Pharmaceuticals Limited generated $61.1M in revenue (+5.5% YoY), $23.1M in net income, and $27.1M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (81% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CUVL trading relative to its 50-day, 200-day, and 52-week technical levels?

CUVL last traded at $5.15 (+1.58% on volume of 8,165 shares), positioning the stock -11.66% below its 50-day simple moving average ($5.83) and -24.15% below its 200-day simple moving average ($6.79). Across its 52-week range of $4.88 to $8.92, CUVL sits at the 6.7% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($4.71 to $5.59).

CUVL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CUVL's 12-month stock price target?

Clinuvel Pharmaceuticals Limited (CUVL) carries a 12-month consensus base price target of $5.34 (+3.7% from $5.15), with a bull-case target of $9.37 and a bear-case floor of $4.17.